BCM
CLYM

BML Capital Management’s Climb Bio CLYM Stock Holding History

BML Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,193,742
Closed -$6.01M – 33
2024
Q1 		$6.01M Buy
2,193,742
+13,742
+0.6% +$37.8K 3.96% 7
2023
Q4 		$5.89M Buy
2,180,000
+241,737
+12% +$629K 4.46% 6
2023
Q3 		$5.1M Buy
1,938,263
+355,093
+22% +$968K 4.68% 8
2023
Q2 		$4.43M Sell
1,583,170
-75,000
-5% -$228K 3.99% 9
2023
Q1 		$4.81M Sell
1,658,170
-166,964
-9% -$573K 4.16% 8
2022
Q4 		$6.7M Buy
+1,825,134
New +$5.41M 6.4% 7

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BML Capital Management's CLYM Position: Q2 2024 in Review

BML Capital Management sold out of Climb Bio (CLYM) in Q2 2024, closing a stake of 2,193,742 shares — an estimated $6.01M sold.

BML Capital Management first reported a position in CLYM in Q4 2022 and held it in 6 quarters. The position peaked at $6.7M in Q4 2022. 47 funds tracked by Wall St. Rank hold CLYM as of Q2 2024.

  • BML Capital Management reported no remaining Climb Bio position as of Q2 2024 after selling out during the quarter.
  • BML Capital Management sold 2,193,742 Climb Bio shares in Q2 2024, an estimated $6.01M.
  • BML Capital Management first reported a position in Climb Bio in Q4 2022 and held it in 6 quarters.
  • BML Capital Management's Climb Bio position peaked at $6.7M in Q4 2022.
  • 47 funds tracked by Wall St. Rank held Climb Bio as of Q2 2024.

Based on BML Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.